Solural Pharma ApS publish phase 1 clinical results of its oral irinotecan product in Cancer Chemotherapy and Pharmacology: Oral administration of Irinotecan in patients with solid tumor: An open label phase 1, dose escalation study evaluating safety, tolerability and pharmacokinetics
Recent news
- New patent acquisition agreement November 16, 2022
- New Eurasia patent December 25, 2020
- New Manufacturing Authorisation December 18, 2020
Career
If you are interested in joining Solural Pharma ApS, we are seeking professionals, technicians and consultants with expertise within drug development. Please contact
career@soluralpharma.com for more information about available positions.